While the company has yet to disclose the pricing or the specific volume of shares to be offered, the move marks a significant step in its transition toward commercial-stage development. Aspen Neuroscience intends to channel the capital raised through this offering into its primary pipeline project, a cell therapy candidate known as sasineprocel.

Designed as a treatment for Parkinson's disease, the therapy represents the core of the company's clinical focus. By tapping into public markets, Aspen joins a competitive sector of biotech firms attempting to leverage regenerative medicine to address neurodegenerative conditions. The filing provides the first formal look at the company’s capital structure as it prepares to bring its proprietary cell replacement technology to a broader investor base.